Abbisko Cayman Limited (HKG:2256)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
11.88
+0.54 (4.76%)
At close: Mar 6, 2026
Market Cap7.99B +159.1%
Revenue (ttm)681.17M +21.5%
Net Income61.48M +95.2%
EPS0.10 +125.0%
Shares Out672.36M
PE Ratio118.62
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,289,000
Average Volume1,620,281
Open11.47
Previous Close11.34
Day's Range11.47 - 11.96
52-Week Range5.52 - 19.78
Beta1.37
RSI40.52
Earnings DateMar 2, 2026

About Abbisko Cayman

Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People’s Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal trial products comprising Mavorixafor (ABSK081), a CXCR4 modulator to treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome; a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 226
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2256
Full Company Profile

Financial Performance

In 2025, Abbisko Cayman's revenue was 612.12 million, an increase of 21.45% compared to the previous year's 503.99 million. Earnings were 55.25 million, an increase of 95.21%.

Financial numbers in CNY Financial Statements